Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.
- Hendricksen K Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: k.hendricksen@nki.nl.
- Aziz A Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Bes P Ipsen Pharma, Boulogne-Billancourt, France.
- Chun FK Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Dobruch J Department of Urology, Centre of Postgraduate Medical Education, European Health Centre Otwock, Poland.
- Kluth LA Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Gontero P Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Torino, Italy.
- Necchi A Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Noon AP Department of Urology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
- van Rhijn BWG Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Rink M Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Roghmann F Department of Urology, Ruhr-University Bochum, Marien Hospital Herne, Herne, Germany.
- Rouprêt M Department of Urology, Pitié Salpétrière Hospital, Assistance Publique - Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, Université Paris 6, Paris, France.
- Seiler R Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada; Department of Urology, University of Bern, Bern, Switzerland.
- Shariat SF Department of Urology, Medical University of Vienna, Vienna, Austria.
- Qvick B Ipsen Pharma, Boulogne-Billancourt, France.
- Babjuk M Department of Urology, 2nd Faculty of Medicine, Charles University in Praha Motol University, Praha, Czech Republic.
- Xylinas E Department of Urology, Cochin Hospital, Assistance-Publique Hôpitaux de Paris, Paris Descartes University, Paris, France.
- 2017-10-28
Published in:
- European urology focus. - 2019
Clinical practice
Non–muscle-invasive bladder cancer
Physician
Survey
Treatment guidelines
Urologist
Europe
Health Care Surveys
Humans
Neoplasm Invasiveness
Practice Guidelines as Topic
Practice Patterns, Physicians'
Urinary Bladder Neoplasms
English
BACKGROUND
The European Association of Urology (EAU) non-muscle-invasive bladder cancer (NMIBC) guidelines are meant to help minimise morbidity and improve the care of patients with NMIBC. However, there may be underuse of guideline-recommended care in this potentially curable cohort.
OBJECTIVE
To assess European physicians' current practice in the management of NMIBC and evaluate its concordance with the EAU 2013 guidelines.
DESIGN, SETTING, AND PARTICIPANTS
Initial 45-min telephone interviews were conducted with 20 urologists to develop a 26-item questionnaire for a 30-min online quantitative interview. A total of 498 physicians with predefined experience in treatment of NMIBC patients, from nine European countries, completed the online interviews.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
Descriptive statistics of absolute numbers and percentages of the use of diagnostic tools, risk group stratification, treatment options chosen, and follow-up regimens were used.
RESULTS AND LIMITATIONS
Guidelines are used by ≥87% of physicians, with the EAU guidelines being the most used ones (71-100%). Cystoscopy (60-97%) and ultrasonography (42-95%) are the most used diagnostic techniques. Using EAU risk classification, 40-69% and 88-100% of physicians correctly identify all the prognostic factors for low- and high-risk tumours, respectively. Re-transurethral resection of the bladder tumour (re-TURB) is performed in 25-75% of low-risk and 55-98% of high-risk patients. Between 21% and 88% of patients received a single instillation of chemotherapy within 24h after TURB. Adjuvant intravesical treatment is not given to 6-62%, 2-33%, and 1-20% of the patients with low-, intermediate-, and high-risk NMIBC, respectively. Patients with low-risk NMIBC are likely to be overmonitored and those with high-risk NMIBC undermonitored. Our study is limited by the possible recall bias of the selected physicians.
CONCLUSIONS
Although most European physicians claim to apply the EAU guidelines, adherence to them is low in daily practice.
PATIENT SUMMARY
Our survey among European physicians investigated discrepancies between guidelines and daily practice in the management of non-muscle-invasive bladder cancer (NMIBC). We conclude that the use of the recommended diagnostic tools, risk-stratification of NMIBC, and performance of re-TURB have been adopted, but adjuvant intravesical treatment and follow-up are not uniformly applied.
The European Association of Urology (EAU) non-muscle-invasive bladder cancer (NMIBC) guidelines are meant to help minimise morbidity and improve the care of patients with NMIBC. However, there may be underuse of guideline-recommended care in this potentially curable cohort.
OBJECTIVE
To assess European physicians' current practice in the management of NMIBC and evaluate its concordance with the EAU 2013 guidelines.
DESIGN, SETTING, AND PARTICIPANTS
Initial 45-min telephone interviews were conducted with 20 urologists to develop a 26-item questionnaire for a 30-min online quantitative interview. A total of 498 physicians with predefined experience in treatment of NMIBC patients, from nine European countries, completed the online interviews.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
Descriptive statistics of absolute numbers and percentages of the use of diagnostic tools, risk group stratification, treatment options chosen, and follow-up regimens were used.
RESULTS AND LIMITATIONS
Guidelines are used by ≥87% of physicians, with the EAU guidelines being the most used ones (71-100%). Cystoscopy (60-97%) and ultrasonography (42-95%) are the most used diagnostic techniques. Using EAU risk classification, 40-69% and 88-100% of physicians correctly identify all the prognostic factors for low- and high-risk tumours, respectively. Re-transurethral resection of the bladder tumour (re-TURB) is performed in 25-75% of low-risk and 55-98% of high-risk patients. Between 21% and 88% of patients received a single instillation of chemotherapy within 24h after TURB. Adjuvant intravesical treatment is not given to 6-62%, 2-33%, and 1-20% of the patients with low-, intermediate-, and high-risk NMIBC, respectively. Patients with low-risk NMIBC are likely to be overmonitored and those with high-risk NMIBC undermonitored. Our study is limited by the possible recall bias of the selected physicians.
CONCLUSIONS
Although most European physicians claim to apply the EAU guidelines, adherence to them is low in daily practice.
PATIENT SUMMARY
Our survey among European physicians investigated discrepancies between guidelines and daily practice in the management of non-muscle-invasive bladder cancer (NMIBC). We conclude that the use of the recommended diagnostic tools, risk-stratification of NMIBC, and performance of re-TURB have been adopted, but adjuvant intravesical treatment and follow-up are not uniformly applied.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1016/j.euf.2017.09.002
- PMID 29074050
- Persistent URL
- https://folia.unifr.ch/global/documents/190755
Statistics
Document views: 21
File downloads:
- fulltext.pdf: 0